

Design, Synthesis and Bioactivity Evaluation of Novel Isoxazole-Amide Derivatives Containing an Acylhydrazone Moiety as New Active Antiviral Agents

Zai-Bo Yang ^{1,*,+}, Pei Li ^{1,2,*,+} and Yin-Ju He ¹

¹ School of Chemistry and Chemical Engineering, Qiannan Normal University for Nationalities, Duyun 558000, China; heyinju2007@163.com

² Qiandongnan Engineering and Technology Research Center for Comprehensive Utilization of National Medicine, Kaili University, Kaili 556011, China

* Correspondence: yzb1976110@sohu.com (Z-B.Y.); pl19890627@126.com (P.L.); Tel.: +86(854)873-7046

+ These authors contributed equally to this work.

Table S1. The preliminary in vivo antiviral activities against TMV and CMV of the target compounds

7a–7v at 500 mg/L.

Compound s	TMV			CMV		
	Curative activity (%)	Protection activity (%)	Inactivation activity (%)	Curative activity (%)	Protection activity (%)	Inactivation activity (%)
7a	48.5 ± 3.0	54.2 ± 3.1	85.6 ± 1.7	38.4 ± 1.2	47.6 ± 1.3	69.9 ± 1.5
7b	40.8 ± 2.1	46.5 ± 5.0	83.4 ± 2.1	33.6 ± 1.4	44.7 ± 1.8	65.8 ± 1.7
7c	39.4 ± 1.3	59.4 ± 2.2	87.7 ± 2.3	37.9 ± 1.9	54.6 ± 2.1	72.6 ± 2.4
7d	62.9 ± 1.2	67.2 ± 3.0	93.6 ± 3.3	56.7 ± 2.1	63.8 ± 2.5	91.4 ± 2.6
7e	28.2 ± 3.1	39.8 ± 2.1	55.1 ± 2.9	14.4 ± 1.3	24.6 ± 1.5	42.3 ± 1.2
7f	36.7 ± 1.4	50.2 ± 4.2	78.8 ± 1.6	33.5 ± 1.6	43.6 ± 2.3	76.9 ± 2.1
7g	35.6 ± 2.2	42.4 ± 1.7	74.7 ± 1.8	30.7 ± 1.8	40.5 ± 1.4	70.8 ± 1.9
7h	64.5 ± 1.2	69.6 ± 2.6	94.1 ± 1.2	58.8 ± 2.2	65.4 ± 2.5	92.0 ± 2.6
7i	50.4 ± 1.2	58.2 ± 2.3	86.4 ± 1.9	47.3 ± 1.6	54.7 ± 2.1	80.7 ± 1.8
7j	55.4 ± 1.3	65.3 ± 1.1	92.6 ± 3.2	51.6 ± 1.7	57.5 ± 1.6	81.8 ± 2.7
7k	47.5 ± 1.1	56.4 ± 2.3	85.5 ± 3.7	48.3 ± 1.5	54.8 ± 2.2	78.4 ± 2.6
7l	43.9 ± 4.2	60.4 ± 4.1	89.4 ± 3.3	41.6 ± 1.8	56.2 ± 2.4	75.8 ± 2.3
7m	65.1 ± 2.2	69.7 ± 1.0	95.3 ± 2.6	58.6 ± 2.5	64.4 ± 1.7	92.8 ± 2.8
7n	36.5 ± 1.0	43.6 ± 1.2	67.5 ± 1.8	26.5 ± 1.1	34.8 ± 1.4	52.9 ± 1.3
7o	42.2 ± 4.5	56.3 ± 1.5	84.2 ± 2.1	39.6 ± 2.2	49.7 ± 1.6	75.8 ± 2.5
7p	40.9 ± 4.1	49.4 ± 1.0	78.2 ± 1.4	36.2 ± 2.0	44.8 ± 1.4	69.9 ± 1.8
7q	67.0 ± 2.3	72.7 ± 2.2	96.3 ± 1.5	60.8 ± 2.7	67.8 ± 2.9	93.8 ± 1.9
7r	56.7 ± 2.1	64.3 ± 2.3	93.3 ± 3.1	57.9 ± 2.5	63.6 ± 2.4	91.9 ± 2.8
7s	52.3 ± 1.6	60.3 ± 4.1	89.1 ± 1.3	47.7 ± 1.8	52.2 ± 2.3	80.6 ± 1.5
7t	68.8 ± 2.5	74.8 ± 2.6	96.9 ± 2.9	65.9 ± 2.8	70.2 ± 2.5	94.6 ± 2.4
7u	40.5 ± 2.2	57.4 ± 2.0	76.9 ± 1.2	36.2 ± 2.1	48.9 ± 2.2	68.7 ± 2.3
7v	37.2 ± 3.1	42.5 ± 3.0	67.7 ± 2.8	31.4 ± 1.2	38.6 ± 1.4	62.0 ± 2.5
NNM	55.6 ± 1.6	63.8 ± 2.9	92.5 ± 1.3	54.7 ± 3.4	62.6 ± 2.5	91.0 ± 3.0

Table S2. The EC₅₀ values of the target compounds 7a–7v against TMV in vivo.

Compounds	EC ₅₀ (mg/L)		
	Curative activity	Protection activity	Inactivation activity
7a	358.5 ± 3.4	256.5 ± 3.4	97.8 ± 1.6
7b	395.8 ± 3.1	324.7 ± 3.2	132.8 ± 1.9
7c	356.8 ± 3.2	288.6 ± 2.8	105.6 ± 1.8
7d	238.9 ± 1.9	187.2 ± 2.4	46.7 ± 1.2
7e	536.3 ± 3.7	429.8 ± 2.9	245.1 ± 2.3
7f	370.7 ± 3.5	290.7 ± 3.8	148.9 ± 2.6
7g	395.6 ± 3.2	322.6 ± 2.2	171.5 ± 2.1
7h	195.5 ± 2.3	172.6 ± 2.8	43.1 ± 1.5
7i	516.7 ± 3.2	345.2 ± 2.6	86.4 ± 1.2
7j	291.4 ± 3.1	232.3 ± 2.6	52.9 ± 1.5
7k	364.5 ± 3.5	276.8 ± 2.9	118.7 ± 1.7
7l	336.8 ± 4.7	249.4 ± 4.5	95.8 ± 1.6
7m	189.9 ± 2.5	176.5 ± 2.5	44.5 ± 1.5
7n	487.6 ± 4.8	361.7 ± 2.7	228.5 ± 2.3
7o	368.6 ± 4.3	280.3 ± 3.3	123.7 ± 2.6
7p	385.6 ± 4.1	299.8 ± 3.2	146.8 ± 2.5
7q	179.6 ± 3.5	169.2 ± 2.9	36.9 ± 1.8
7r	266.8 ± 2.9	199.4 ± 3.5	42.7 ± 1.6
7s	332.3 ± 3.2	296.5 ± 3.5	80.6 ± 1.4
7t	168.5 ± 1.9	157.6 ± 2.1	33.7 ± 1.7

7u	417.8 ± 2.8	377.1 ± 2.3	172.4 ± 3.6
7v	448.9 ± 3.7	421.6 ± 3.5	197.7 ± 3.8
NNM	286.4 ± 2.2	198.2 ± 2.1	46.3 ± 1.9

Table S3. The EC₅₀ values of the target compounds **7a–7v** against CMV in vivo.

Compounds	EC₅₀ (mg/L)		
	Curative activity	Protection activity	Inactivation activity
7a	365.2 ± 3.6	338.6 ± 3.2	114.5 ± 1.9
7b	378.2 ± 3.8	357.7 ± 3.5	138.2 ± 2.3
7c	387.6 ± 3.6	347.4 ± 2.8	147.8 ± 2.3
7d	276.5 ± 2.4	247.8 ± 2.9	57.3 ± 1.9
7e	547.6 ± 3.5	528.2 ± 2.6	318.6 ± 2.9
7f	412.6 ± 3.8	389.3 ± 3.6	193.6 ± 2.9
7g	428.9 ± 3.8	406.4 ± 2.9	223.5 ± 3.2
7h	226.4 ± 3.5	215.8 ± 2.5	53.7 ± 1.8
7i	361.2 ± 3.5	328.7 ± 2.9	108.7 ± 1.3
7j	338.7 ± 3.4	288.9 ± 3.5	93.8 ± 1.8
7k	355.5 ± 3.9	319.6 ± 2.5	105.4 ± 1.9
7l	358.8 ± 4.2	331.5 ± 3.6	129.6 ± 1.8
7m	248.5 ± 3.6	198.3 ± 3.2	51.8 ± 1.4
7n	519.9 ± 4.7	488.3 ± 4.5	287.8 ± 2.9
7o	395.4 ± 3.7	379.8 ± 3.4	169.2 ± 2.9
7p	407.4 ± 4.2	389.4 ± 3.6	192.3 ± 2.8
7q	227.3 ± 3.2	179.7 ± 2.5	47.6 ± 1.9
7r	268.5 ± 2.6	236.9 ± 3.2	56.4 ± 1.4
7s	353.7 ± 3.5	342.7 ± 3.6	89.4 ± 1.3
7t	197.9 ± 2.8	168.4 ± 2.8	45.8 ± 1.2
7u	438.9 ± 3.6	422.8 ± 2.9	226.8 ± 3.9
7v	456.7 ± 3.9	438.9 ± 3.9	234.6 ± 3.6
NNM	297.3 ± 1.4	263.4 ± 2.5	62.8 ± 1.8




Figure S1. The antiviral activity of compound **7t** against TMV at 500 mg/L. Left: smeared with solvent; Right: smeared with compound **7t** or NNM.







Figure S2. The antiviral activity of compound 7t against CMV at 500 mg/L. Left: smeared with solvent; Right: smeared with compound 7t or NNM.




7a




¹H NMR of Compound 7a




¹³C NMR of Compound 7a





4b




¹H NMR of Compound 7b





¹³C NMR of Compound 7b




¹H NMR of Compound 7c





¹³C NMR of Compound 7c




¹H NMR of Compound 7d




¹³C NMR of Compound 7d




¹H NMR of Compound 7e




¹³C NMR of Compound 7e





7f




¹H NMR of Compound 7f





¹³C NMR of Compound 7f




¹H NMR of Compound 7g




¹³C NMR of Compound 7g




¹H NMR of Compound 7h




¹³C NMR of Compound 7h




7i




¹H NMR of Compound 7i




¹³C NMR of Compound 7i





7j




¹H NMR of Compound 7j





¹³C NMR of Compound 7j




¹H NMR of Compound 7k





¹³C NMR of Compound 7k




¹H NMR of Compound 71



¹³C NMR of Compound 71



¹H NMR of Compound 7m



```



Filename = abc_13041c_yab55-4_c_
Author = delta
Experiment = single_pulse_dec
Sample_id = yab55-4
Solvent = DMSO-d6
Creation_time = 16-APR-2013 17:44:53
Revision_time = 2-MAY-2013 17:10:46
Current_time = 2-MAY-2013 17:11:17

Comment = single pulse decouple
Data_format = 1D_COMPLEX
Dim_size = 6214
Dim_title = 13c
Dim_units = [ppm]
Dimensions = 2
Site = FCC 500M
Spectrometer = DELTA2_NMR


Field_strength = 11.747379 [T] (500 MHz)
X_acq_duration = 0.83361792 [s]
X_domain = 13c
X_freq = 125.76529768 [MHz]
X_offset = 120 [ppm]
X_pulses = 12748
X_pulseprog = 4
X_resolution = 1.19550034 [Hz]
X_sweep = 19.3081762 [kHz]
Xr_domain = 18
Xr_freq = 500.15991521 [MHz]
Xr_offset = 6.0 [ppm]
Xr_pulse = 1
Incomplete_copy = TRUE
Mod_return = 1
Scans = 3712
Total_scans = 3712

X_90_width = 9.4 [us]
X_acq_time = 0.83361792 [s]
X_echo = 30 [us]
X_atn = 6.3 [dB]
X_pulse = 3.13333333 [us]
Xr_atn_dec = 18.193 [dB]
Xr_atn_inc = 18.193 [dB]
Xr_noise = WALTZ
Decoupling = DPMO
Initial_wait = 1 [s]
Max = 2 [s]
Recvr_gain = 52
Relaxation_delay = 2 [s]
Repetition_time = 2.93361792 [s]
Temp_pt = 21.9 [deg]
  
```



¹³C NMR of Compound 7m




¹H NMR of Compound 7n





¹³C NMR of Compound 7n




¹H NMR of Compound 7o





¹³C NMR of Compound 7o




¹H NMR of Compound 7p





¹³C NMR of Compound 7p




¹H NMR of Compound 7q





¹³C NMR of Compound 7q




¹H NMR of Compound 7r





¹³C NMR of Compound 7r




¹H NMR of Compound 7s





¹³C NMR of Compound 7s




¹H NMR of Compound 7t





¹³C NMR of Compound 7t




¹H NMR of Compound 7u



¹³C NMR of Compound 7u



¹H NMR of Compound 7v



JEOL

```

Filename      = sba_20130327_yhb55-14
Author       =
Experiment   = single_pulse_dec
Sample_id    = yhb55-14
Solvent      = DMSO-d6
Creation_time = 28-MAR-2013 08:21:17
Revision_time = 28-MAR-2013 19:35:54
Current_time  = 29-MAR-2013 19:36:27

Comment      = single pulse decouple
Data format  = 1D COMPLEX
Dia_size     = 25214
Dia_title    = 13C
Dia_units    = (ppm)
Dimensions   = X
Site         = BXC 500M
Spectrometer = DELTA2_300M

Field_strength = 11.747379 (T) (500 MHz)
X_acq_duration = 0.83361792 (s)
X_domain      = 13C
X_freq        = 125.76529748 (MHz)
X_offset      = 130 (ppm)
X_points      = 32768
X_prescans    = 4
X_resolution  = 1.19959034 (Hz)
X_sweep       = 35.9081761 (Hz/s)
Int_domain    = 1H
Int_freq      = 500.1591521 (MHz)
Int_offset    = 5.0 (ppm)
Clipped      = 1608
Mod_return    = 1
Snooze       = 13432
Total_scans   = 13432

X_90_width    = 9.4 (use)
X_acq_time    = 0.83361792 (s)
X_angle       = 30 (deg)
X_atn         = 6.3 (dB)
X_pulse       = 3.1333333 (use)
Int_atn_dec   = 18.193 (dB)
Int_atn_noise = 18.193 (dB)
Decoupling    = WALTZ
Initial_wait  = 1 (s)
Noise         = 1908
New_time      = 2 (s)
Recvr_gain    = 5 (s)
Relaxation_delay = 2 (s)
Repetition_time = 2.83361792 (s)
Temp_get      = 22.5 (deg)
  
```

¹³C NMR of Compound 7v